B7-H5, a costimulatory polypeptide

Patent metadata

Field	Value
Publication number	US-10501520-B2
Application number	US-201715845158-A
Country	US
Kind code	B2
Filing date	Dec 18, 2017
Priority date	Jun 24, 2004
Publication date	Dec 10, 2019
Grant date	Dec 10, 2019

Abstract

B7-H5 costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein.

First claim

I claim:

1. A composition comprising a fusion protein and a pharmaceutically acceptable carrier, wherein the fusion protein comprises:
a first domain that consists of an amino acid sequence encoded by a nucleic acid sequence that encodes a protein consisting of an extracellular region of a protein, wherein the nucleic acid sequence hybridizes over its full length, after a wash at 50° C. to 60° C. in a buffer containing 0.2×SSC and 0.1% SDS, to the complement of a nucleotide sequence consisting of nucleotide 88 to nucleotide 936 of SEQ ID NO:2; and
at least one additional domain comprising an amino acid sequence that is unrelated to SEQ ID NO:1.

2. The composition of claim 1 , wherein the at least one additional domain is all or part of an immunoglobulin heavy chain constant region.

3. The composition of claim 1 , wherein said fusion protein comprises amino acid 40 to amino acid 190 of SEQ ID NO:1.

4. The composition of claim 1 , wherein said fusion protein comprises amino acid 35 to amino acid 190 of SEQ ID NO:1.

5. The composition of claim 1 , wherein said fusion protein comprises amino acid 30 to amino acid 190 of SEQ ID NO:1.

6. The composition of claim 1 , wherein said nucleic acid sequence hybridizes over its full length, after a wash at 50° C. to 60° C. in a buffer containing 0.2×SSC and 0.1% SDS, to the complement of a nucleotide sequence consisting of nucleotide 88 to nucleotide 570 of SEQ ID NO:2.

7. The composition of claim 1 , wherein said pharmaceutically acceptable carrier is physiological saline.

8. A composition comprising a fusion protein and a pharmaceutically acceptable carrier, wherein said fusion protein comprises:
a first domain consisting of a polypeptide that consists of all or part of amino acid 30 to amino acid 311 of SEQ ID NO:1 and includes at least an V-like Ig domain consisting of amino acid 47 to amino acid 150 of SEQ ID NO:1; and
at least one additional domain comprising an amino acid sequence that is unrelated to SEQ ID NO:1.

9. The composition of claim 8 , wherein said at least one additional domain is all or part of an immunoglobulin heavy chain constant region.

10. The composition of claim 8 , wherein said fusion protein comprises amino acid 40 to amino acid 311 of SEQ ID NO: 1.

11. The composition of claim 8 , wherein said fusion protein comprises amino acid 35 to amino acid 311 of SEQ ID NO:1.

12. The composition of claim 8 , wherein said fusion protein comprises amino acid 30 to amino acid 311 of SEQ ID NO:1.

13. The composition of claim 8 , wherein said pharmaceutically acceptable carrier is physiological saline.

Assignees

• Mayo Found Medical Education & Res

Inventors

• Chen Lieping

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• C07K14/70532 Primary

  B7 molecules, e.g. CD80, CD86 · CPC title

• C07K16/18

  against material from animals or humans · CPC title

• C07K16/46

  Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00) · CPC title

• C07K2319/70

  containing domain for protein-protein interaction · CPC title